Lundbeck
Tracked across 8 events · 51 articles · First seen Apr 13, 2026 · Last active Aug 19, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Lundbeck is presenting new data across its neurology portfolio, including bocunebart, eptinezumab, and bexicaserin, at the American Academy of Neurology Annual Meeting 2026, highlighting its commitment to advancing brain disease treatments.
Apr 13, 2026 · 6 articles
Business
Impact: Lundbeck received orphan drug designation in Japan for asedebart, which is a positive development for the company's pipeline and market reach in rare diseases.
May 18, 2026 · 7 articles
Business
Impact: Lundbeck received marketing authorization for its migraine treatment, eptinezumab, in South Korea, expanding its global market presence and potential revenue.
May 26, 2026 · 7 articles
Tech
Impact: Lundbeck announced positive preliminary Phase II Part A data for asedebart in Cushing's disease, which is encouraging for its drug development pipeline and future market position in rare endocrine disorders.
Jun 14, 2026 · 6 articles
Business
Impact: Lundbeck achieved a key enrollment milestone for its lead pipeline asset bexicaserin, advancing toward potential approval in DEEs.
Jul 20, 2026 · 6 articles
Regulatory
Impact: Lundbeck received FDA Fast Track designation for its lead orexin 2 receptor agonist, Lu AH69593, for narcolepsy. This regulatory milestone supports its R&D pipeline and may expedite development.
Jul 23, 2026 · 6 articles
Business
Lundbeck reported strong financial results for the first half of 2026, with total revenue growing 16% CER to DKK 13,588 million, driven by strong performance of Eptinezumab and Brexpiprazole. Adjusted EBITDA rose 19% CER to…
Impact: Core entity reporting strong H1 2026 results with revenue and earnings growth, pipeline advancements, and strategic partnerships, positively impacting its financial position and market perception.
Jul 20, 2026 · 7 articles
Business
On August 19, 2026, Lundbeckfond Invest A/S, a fully owned subsidiary of the Lundbeck Foundation and major shareholder in Lundbeck, launched a voluntary exchange offer to eligible A-shareholders in Lundbeck. Lundbeck has informed Lundbeckfond Invest…
Impact: Lundbeck is the target of the exchange offer, with its A-shares being exchanged. The company's participation indicates support for the offer, which may affect its shareholder base and governance.
Aug 19, 2026 · 6 articles
100
Lundbeckfond Invest A/S launched exchange offer LundbeckLundbeckfond Invest...
90
Lundbeck reported revenue growthLundbeck H1 2026 revenue growth
80
Lundbeck raised EPSLundbeck H1 2026 revenue growth
70
United States — Food and Drug Administration granted Fast Track designation LundbeckLundbeck H1 2026 revenue growth
60
Lundbeck randomized last patientLundbeck H1 2026 revenue growth
50
Lundbeck announced dataLundbeck H1 2026 revenue growth
50
Lundbeck presented clinical dataLundbeck H1 2026 revenue growth
40
Lundbeck partnered with Cradle CradleLundbeck H1 2026 revenue growth
40
Bangladesh — Ministry of Health and Family Welfare granted designation LundbeckLundbeck H1 2026 revenue growth
40
South Korea — Ministry of Food and Drug Safety granted marketing authorization LundbeckLundbeck H1 2026 revenue growth
ERGEN INTELLIGENCE
Track Lundbeck live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard